妓院一钑片免看黄大片,亚洲av无码成人精品国产,亚洲AV综合色区无码专区桃色,免费A级毛片在线播放不收费

Agenix   
Agenix創建于1982年，該公司是基于昆士蘭理工學院成立的一個生物制藥和研究集團，該公司的主要業務是研發單克隆抗體診斷程序。該公司擁有兩個全資子公司，其中一個為Agen Biomedical，另一個為Agenix Biopharmaceutical，后者位于中國上海。

Agenix listed on the Australian Securities Exchange in 1987. Today, Agenix’s lead product
candidate is ThromboView?, a novel radio-labelled monoclonal antibody imaging modality for
pulmonary embolism (PE) and deep vein thrombosis (DVT). ThromboView? has successfully
completed two U. S.  FDA Phase II clinical trials and is in partnering discussions for Phase III trials.

Agenix’s human health diagnostics platform, DiagnostIQ? is a patented disposable point-ofcare test device with reader. DiagnostIQ? utilises an antibody/antigen printed membrane, a unique pre-filter device and an incubation chamber in a flow-through format to create a
sensitive and quantitative, rapid, test. The patented technology provides the potential for point-of-need testing that is simple and quick to use, gives rapid and accurate results. Agricultural rights for the platform are licensed to Bayer CropSciences AG.

Agenix has completed pre-clinical studies on AGX 1009, a next-generation reverse
transcriptase inhibitor (NtRTI) prodrug of tenofovir. Agenix plans to divest this project and exit
China operations following filing of the CFDA clinical trial application in 3Q 2013 to focus on its
diagnostics business. Agenix owns all the patent rights to both ThromboView? and AGX 1009.